Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial
Mart M, Boehm L, Kiehl A, Gong M, Malhotra A, Owens R, Khan B, Pisani M, Schmidt G, Hite R, Exline M, Carson S, Hough C, Rock P, Douglas I, Feinstein D, Hyzy R, Schweickert W, Bowton D, Masica A, Orun O, Raman R, Pun B, Strength C, Rolfsen M, Pandharipande P, Brummel N, Hughes C, Patel M, Stollings J, Ely E, Jackson J, Girard T. Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine 2024, 12: 599-607. PMID: 38701817, PMCID: PMC11296889, DOI: 10.1016/s2213-2600(24)00077-8.Peer-Reviewed Original ResearchEffects of antipsychotic treatmentCognitive impairmentAssociated with long-term cognitive impairmentTreat deliriumLong-term cognitive impairmentLong-term outcomesTreatment of deliriumCritically ill patientsAntipsychotic treatmentZiprasidone groupHaloperidol groupFollow-upQuality-of-life outcomesAssessed survivorsZiprasidoneHaloperidolAntipsychoticsCognitive outcomesTreatment group assignmentDepartment of Veterans AffairsQuality-of-lifeIll patientsPlacebo-controlledCritical illnessLong-term follow-up